CPC Class C12Q

The present invention relates to a plant biotic agent phenotyping platform comprising a container hermetically sealed with a lid delimiting an internal space divided into two spaces: -a lower internal space which comprises at least one temperature control means immersed in a temperature transfer liquid; and -an upper internal space, the surface of the temperature transfer liquid being the border between the lower internal space and the upper internal space; the lid comprising at least one orifice which is adapted to fit a pot and at least one pot whose bottom part is contained in the upper internal space and which is adapted to receive plant seeds and soil parasite and to enable development of such soil parasites and plants. The invention also related to the use of this platform for screening plant resistance or tolerance to soil parasite.

An identified 90 bp sequence insertion in the GB0331 genome disrupts the coding sequence of the FAD2-1D gene near the 3′ end of the protein coding region. This sequence is not found in reference genomes of other Gossypium species. This DNA segment can be used to track the high oleic fad-2-1D mutant allele for introgression into cotton varieties such as Pima and upland cotton varieties. This enables a non-GMO strategy to elevate the oleic acid content of commercial cottonseed oil.

The present invention is in the field of plant breeding and aphid resistance. More specifically, the invention includes a method for breeding soybean plants containing quantitative trait loci that are associated with resistance to aphids, Aphis glycines. The invention further includes method for monitoring the introgression quantitative trait loci (QTL) conferring aphid resistance into elite germplasm in a breeding program.

A method for treating patients afflicted with cancer, wherein the patients are treated with a compound including tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, in particular masitinib, optionally in combination with at least one antineoplastic agent. The tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, and the optional at least one antineoplastic agent, are administered in a dosage regimen that includes a therapeutically effective amount. Also described are methods for predicting therapeutic response to the treatment in a given patient and therefore identification of applicable patient subpopulations based upon these predictor factors; sometimes referred to as biomarkers. One method is based upon the clinical marker of pain intensity. Another method is based upon gene expression predictive biomarkers assessed via RNA expression in peripheral blood cell samples collected prior to treatment with the compound, which is also used for treating patients afflicted with pancreatic cancer.